Sanofi's new R&D chief said on Wednesday Western drugmakers cannot ignore China's accelerating innovation and should consider ...
Ultragenyx sold 2 PRVs for $203M and $210M; Biomea's BMF-650 showed modest weight loss; Skyhook Bio shutters; Altay raises ...
FDA launches Rare Disease Framework Initiative to tailor reviews by disease, with a stakeholder meeting set for Oct. 28.
Arrowhead Pharmaceuticals' ARO-MAPT subcutaneous injection reduced tau protein by up to 85% in healthy volunteers, ...
Verastem Oncology announced VS-7375 data showing 41% response rate in pancreatic cancer, raised $250M, and CEO Dan Paterson ...
Gilead pays Vir Biotechnology $65M upfront plus $25M investment for 3 T cell engager solid tumor therapies. Deal includes ...
GSK will make up to 1,217 workers redundant from its sites in Belgium as part of the cost-cutting initiative CEO Luke Miels ...
Beam Therapeutics shared Phase 1/2 data on BEAM-301 for GSDIa; Pfizer partnered with Enodia on Sec61 inhibitors for $500M+; ...
After success with the drug Winrevair, a band of entrepreneurs has found their next challenge in a difficult-to-treat lung disease. On Tuesday, Oorja Bio launched with a $30 million ...
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Heidi, an Australian AI health startup, raised $340M from General Catalyst to pursue FDA approval for AI-driven prescribing ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results